Stock RAPTOR PHARMACEUTICAL CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Raptor Pharmaceutical Corp

Equities

US75382F1066

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Raptor Pharmaceutical Corp
2016 Exclusive: Drugmaker Depomed prepares to explore a sale - sources RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Exclusive: Drugmaker Depomed prepares to explore a sale - sources
RE
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information
BU
Raptor Pharmaceutical : Acquisition May Not Be in the Best Interests of RPTP Shareholders
PR
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Investors To Contact The Firm For Additional Information
BU
RAPTOR PHARMACEUTICAL CORP. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Horizon Pharma plc
BU
Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients
GL
Raptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International Congress
GL
Raptor Pharmaceutical : Voted A "Best Places to Work" Company in the North San Francisco Bay Area
PU
Raptor Pharmaceutical Voted A “Best Places to Work” Company in the North San Francisco Bay Area
GL
Raptor Pharmaceutical : Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma
PR
Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results
GL
Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT
GL
Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference
GL
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR™ at the 39th European Cystic Fibrosis Conference
GL
Raptor Pharmaceutical : to Present Data on QUINSAIR™ at European Cystic Fibrosis Conference
PU
Raptor Pharmaceutical to Present Data on QUINSAIR™ at European Cystic Fibrosis Conference  
GL
Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results
GL
Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET
GL
Raptor Pharmaceutical Launches QUINSAIR™ in Europe
GL
Raptor Pharmaceutical : PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Raptor Pharmaceutical Corp